BeiGene
BGNE
#992
Rank
ยฃ15.58 B
Marketcap
ยฃ140.86
Share price
1.55%
Change (1 day)
-2.17%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2024 (TTM): ยฃ2.57 Billion

According to BeiGene 's latest financial reports the company's current revenue (TTM ) is ยฃ2.60 Billion. In 2023 the company made a revenue of ยฃ1.92 Billion an increase over the revenue in the year 2022 that were of ยฃ1.17 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) ยฃ2.57 B33.48%
2023 ยฃ1.92 B64.9%
2022 ยฃ1.17 B34.31%
2021 ยฃ0.87 B284.56%
2020 ยฃ0.22 B-30.61%
2019 ยฃ0.32 B109.12%
2018 ยฃ0.15 B-11.47%
2017 ยฃ0.17 B20240.54%
2016 ยฃ0.86 M-85.42%
2015 ยฃ5.94 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
ยฃ0.17 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.55 B-78.55%๐Ÿ‡บ๐Ÿ‡ธ USA